5-aminomethyl-6-methylpyridin-2-ylamine hydrochloride | 1860894-41-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-aminomethyl-6-methylpyridin-2-ylamine hydrochloride
• 英文别名: 5-Aminomethyl-6-methyl-pyridin-2-ylamine hydrochloride；5-(aminomethyl)-6-methylpyridin-2-amine;hydrochloride
• CAS: 1860894-41-2
• 化学式: C₇H₁₁N₃*ClH
• 分子量: 173.645
• InChiKey: ZAIAAABEAHWEJG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.85
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  64.9
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-aminomethyl-6-methylpyridin-2-ylamine hydrochloride 在 盐酸 、 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 三乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 9.5h， 生成 (R)-N-[(S)-1-[(6-amino-2-methyl-pyridin-3-ylmethyl)-carbamoyl]-2-(4-fluoro-phenyl)-ethyl]-2-hydroxy-3-phenyl-propionamide trifluoroacetate
  参考文献：
  名称：

  [EN] AMINOPYRIDINE DERIVATIVES AS KALLIKREIN INHIBITORS
  [FR] DÉRIVÉS AMINOPYRIDINE COMME INHIBITEURS DE LA KALLICRÉINE

  摘要：

  本发明提供了式(I)的化合物：包含这种化合物的组合物；在治疗中使用这种化合物（如哮喘或慢性阻塞性肺病）；以及使用这种化合物治疗患者的方法；其中R1-R10和A1如本文所定义。

  公开号：

  WO2011051671A1
• 作为产物：
  描述：

  2-氨基-5-溴-6-甲基吡啶 在 palladium-carbon 盐酸 作用下， 以 甲醇 、 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 5-aminomethyl-6-methylpyridin-2-ylamine hydrochloride
  参考文献：
  名称：

  PYRAZINONE THROMBIN INHIBITORS

  摘要：

  公开号：

  EP0900207B1

文献信息

• [EN] THERAPEUTIC INHIBITORY COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS THÉRAPEUTIQUES
  申请人：LIFESCI PHARMACEUTICALS INC

  公开号：WO2018011628A1

  公开（公告）日：2018-01-18

  Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.

  本文提供了杂环衍生物化合物和包含这些化合物的药物组合物，用于抑制血浆激肽酶。此外，这些化合物和组合物对于治疗血浆激肽酶抑制已被证实有关的疾病，如血管性水肿等，具有益处。
• THERAPEUTIC INHIBITORY COMPOUNDS
  申请人：LifeSci Pharmaceuticals, Inc.

  公开号：US20160200704A1

  公开（公告）日：2016-07-14

  Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.

  本文提供了一些杂环衍生物化合物和含有这些化合物的药物组合物，这些化合物对抑制血浆卡利肌酶具有用处。此外，这些化合物和组合物对于治疗已被认为与血浆卡利肌酶抑制有关的疾病，如血管性水肿等，具有用处。
• Therapeutic inhibitory compounds
  申请人：LifeSci Pharmaceuticals, Inc.

  公开号：US10023557B2

  公开（公告）日：2018-07-17

  Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.

  本文提供的杂环衍生物化合物和药物组合物包含所述化合物，可用于抑制血浆卡利克林。此外，所述化合物和组合物还可用于治疗与血浆卡利克酶抑制作用有关的疾病，如血管性水肿等。
• Efficacious, Orally Bioavailable Thrombin Inhibitors Based on 3-Aminopyridinone or 3-Aminopyrazinone Acetamide Peptidomimetic Templates
  作者：Philip E. J. Sanderson、Terry A. Lyle、Kellie J. Cutrona、Dona L. Dyer、Bruce D. Dorsey、Colleen M. McDonough、Adel M. Naylor-Olsen、I-Wu Chen、Zhongguo Chen、Jacquelynn J. Cook、Carolyn M. Cooper、Stephen J. Gardell、Timothy R. Hare、Julie A. Krueger、S. Dale Lewis、Jiunn H. Lin、Bobby J. Lucas,、Elizabeth A. Lyle、Joseph J. Lynch,、Maria T. Stranieri、Kari Vastag、Youwei Yan、Jules A. Shafer、Joseph P. Vacca

  DOI：10.1021/jm980368v

  日期：1998.11.1

  We have addressed the key deficiency of noncovalent pyridinone acetamide thrombin inhibitor L-374,087 (1), namely, its modest half-lives in animals, by making a chemically stable 3-alkylaminopyrazinone bioisostere for its 3-sulfonylaminopyridinone core. Compound 3 (L-375,378), the closest aminopyrazinone analogue of 1, has comparable selectivity and slightly decreased efficacy but significantly improved pharmacokinetics in rats, dogs, and monkeys to 1. We have developed an efficient and versatile synthesis of 3, and this compound has been chosen for further preclinical and clinical development.
• Metabolism-Directed Optimization of 3-Aminopyrazinone Acetamide Thrombin Inhibitors. Development of an Orally Bioavailable Series Containing P1 and P3 Pyridines
  作者：Christopher S. Burgey、Kyle A. Robinson、Terry A. Lyle、Philip E. J. Sanderson、S. Dale Lewis、Bobby J. Lucas、Julie A. Krueger、Rominder Singh、Cynthia Miller-Stein、Rebecca B. White、Bradley Wong、Elizabeth A. Lyle、Peter D. Williams、Craig A. Coburn、Bruce D. Dorsey、James C. Barrow、Maria T. Stranieri、Marie A. Holahan、Gary R. Sitko、Jacquelynn J. Cook、Daniel R. McMasters、Colleen M. McDonough、William M. Sanders、Audrey A. Wallace、Franklin C. Clayton、Dennis Bohn、Yvonne M. Leonard、Theodore J. Detwiler,、Joseph J. Lynch,、Youwei Yan、Zhongguo Chen、Lawrence Kuo、Stephen J. Gardell、Jules A. Shafer、Joseph P. Vacca

  DOI：10.1021/jm020311f

  日期：2003.2.1

  Recent efforts in the field of thrombin inhibitor research have focused on the identification of compounds with good oral bioavailability and pharmacokinetics. In this manuscript we describe a metabolism-based approach to the optimization of the 3-(2-phenethylamino)-6-methylpyrazinone acetamide template (e.g., 1) which resulted in the,modification of each of the three principal components (i.e., P1, P2, P3) comprising this series. As a result of these studies, several potent thrombin inhibitors (e.g., 20, 24, 25) were identified which exhibit high levels of oral bioavailability and long plasma half-lives.